Key strategic factors for stakeholders in the current global biosimilar market

Drug Discovery Today

Volumn 21, Issue 2, 2016, Pages 208-211

  Casey, Daniel ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; FILGRASTIM; GENERIC DRUG; HUMAN GROWTH HORMONE; INFLIXIMAB;

CLINICAL ASSESSMENT; DRUG APPROVAL; DRUG MARKETING; EUROPE; HEALTH INSURANCE; HUMAN; LAW SUIT; LEARNING CURVE; LONG TERM CARE; PATIENT ATTITUDE; PHYSICIAN ATTITUDE; REVIEW; STRATEGIC PLANNING; DRUG INDUSTRY; INTERNATIONAL COOPERATION;

BIOSIMILAR PHARMACEUTICALS; DRUG INDUSTRY; DRUGS, GENERIC; INTERNATIONALITY;

EID: 84950147387     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.09.008     Document Type: Short Survey

References (9)

1. M. Weise, and et al. Biosimilars: the science of extrapolation Blood 124 2014 3191 3196
2. B.J. Scott, and et al. Biosimilar monoclonal antibodies: a Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation Clin. Pharmacol. 55 Suppl. 3 2015 123 132
3. A.S. Tsiftsoglou, and et al. Development and regulation of biosimilars: current status and future challenges BioDrugs 27 2013 203 211
4. R. Kumar, and J. Singh Biosimilar drugs: current status Int. J. Appl. Basic Med. Res. 4 2014 63 66
5. S.D. Lucio, and et al. Biosimilars: implications for health-system pharmacists Am. J. Health Syst. Pharm. 70 2013 2004 2017
6. F. Huzair, and D. Kale Biosimilars and the long game Trends Biotechnol. 33 2015 250 252
7. H.G. Grabowski Follow-on biologics: data exclusivity and the balance between innovation and competition Nat. Rev. Drug Discov. 7 2008 479 488
8. W.N. Price, and A.K. Rai Are trade secrets delaying biosimilars? Science 348 2015 188 189
9. L. Heinemann, and et al. An overview of current regulatory requirements for approval of biosimilar insulins Diabetes Technol Ther 17 2015 510 526